Comparison of the 2017 EULAR/ACR Criteria with Clinicoserologic Criteria for the Classification of Idiopathic Inflammatory Myopathies in Korean Patients

다국어 초록 (Multilingual Abstract)

Purpose: To investigate correlations between myositis-specific autoantibodies (MSA) or myositis-associated antibodies (MAA) andclinical features, thereby demonstrating the utility of clinicoserologic classification in idiopathic inflammatory myopathies (IIM) patients.
Materials and Methods: We conducted a multicenter study of 108 adult patients (age ≥18 years) who were diagnosed with IIM byPeter and Bohan criteria or 2004 European Neuromuscular Centre (ENMC) criteria. Clinical data were obtained by medical recordreview. Immunoblot assay with Euroline strip (EUROIMMUN, Germany) was performed using the sera of dermatomyositis (DM,n=56), polymyositis (PM, n=45), amyopathic DM (n=5), DM sine dermatitis (n=1), and immune mediated necrotizing myopathy(n=1) patients. Patients were classified based on two classifications: 2017 EULAR/ACR and novel clinicoserologic classification.
Results: According to 2017 EULAR/ACR criteria, DM and PM were the most and the second most frequent entities. Overlap myositiswas the major entity of IIM, and the frequency of PM was significantly lower when applying clinicoserologic classification criteria.
Sixty-nine (63.9%) patients had one or more MSA, and 61 (56.5%) patients had one or more MAA. Interstitial lung disease wasclosely associated with anti-MDA5 and anti-ARS, and DM-specific skin lesions were frequently observed in patients with anti-TIF1γ, anti-SRP, and anti-MDA5.
Conclusion: The clinicoserologic criteria based on MSA/MAA positivity could reflect more precise clinical features of IIM. Establishmentof a laboratory system routinely available to screen for MSA/MAA status will be beneficial to provide precise diagnosisand proper management of IIM patients.

참고문헌 (Reference)

1 Witt LJ, "The diagnosis and treatment of antisynthetase syndrome" 23 : 218-226, 2016

2 Gunawardena H, "The clinical features of myositis-associated autoantibodies : a review" 52 : 45-57, 2017

3 In Seol Yoo, "The Role of Autoantibodies in Idiopathic Inflammatory Myopathies" 대한류마티스학회 26 (26): 165-178, 2019

4 Marie I, "Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody" 41 : 890-899, 2012

5 Nagaraju K, "Rheumatology" Mosby 1523-1536, 2003

6 Airio A, "Prognosis and mortality of polymyositis and dermatomyositis patients" 25 : 234-239, 2006

7 Bohan A, "Polymyositis and dermatomyositis(second of two parts)" 292 : 403-407, 1975

8 Bohan A, "Polymyositis and dermatomyositis(first of two parts)" 292 : 344-347, 1975

9 Bhansing KJ, "Patients with systemic sclerosis/polymyositis overlap have a worse survival rate than patients without It" 43 : 1838-1843, 2016

10 Nuño-Nuño L, "Overlap myositis, a distinct entity beyond primary inflammatory myositis : a retrospective analysis of a large cohort from the REMICAM registry" 22 : 1393-1401, 2019

11 Troyanov Y, "Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients" 84 : 231-249, 2005

12 Betteridge Z, "Myositis-specific autoantibodies : an important tool to support diagnosis of myositis" 280 : 8-23, 2016

13 Colafrancesco S, "Inflammatory myopathies and overlap syndromes : update on histological and serological profile" 29 : 810-825, 2015

14 Dalakas MC, "Inflammatory muscle diseases" 372 : 1734-1747, 2015

15 Mammen AL, "Increased frequency of DRB1*11:01 in anti-hydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy" 64 : 1233-1237, 2012

16 Senécal JL, "Editorial : a new classification of adult autoimmune myositis" 69 : 878-884, 2017

17 Fiorentino DF, "Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis" 72 : 449-455, 2015

18 Wolstencroft PW, "Dermatomyositis clinical and pathological phenotypes associated with myositis-specific autoantibodies" 20 : 28-, 2018

19 Jung M, "Canadian Scleroderma Research Group (CSRG). Myopathy is a poor prognostic feature in systemic sclerosis: results from the Canadian Scleroderma Research Group (CSRG) cohort" 43 : 217-220, 2014

20 Palterer B, "Bench to bedside review of myositis autoantibodies" 16 : 5-, 2018

21 Sato S, "Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis" 52 : 1571-1576, 2005

22 McHugh NJ, "Autoantibodies in myositis" 14 : 290-302, 2018

23 Tansley SL, "Autoantibodies in juvenile-onset myositis : their diagnostic value and associated clinical phenotype in a large UK cohort" 84 : 55-64, 2017

24 Targoff IN, "Antibody to signal recognition particle in polymyositis" 33 : 1361-1370, 1990

25 Ghirardello A, "Anti-Mi-2 antibodies" 38 : 79-83, 2005

26 Hirakata M, "Anti-KS : identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease" 162 : 2315-2320, 1999

27 Satoh M, "A comprehensive overview on myositis-specific antibodies : new and old biomarkers in idiopathic inflammatory myopathy" 52 : 1-19, 2017

28 Lundberg IE, "2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups" 76 : 1955-1964, 2017

29 Hoogendijk JE, "119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands" 14 : 337-345, 2004